Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a25119989c95f49c

Jump to content

// Workers AI · dad joke modeWho's Michael Albeck? Albeck to the future.

From Wikipedia, the free encyclopedia
Michael Albeck
מיכאל אלבק
BornOctober 1934 (age 91)
CitizenshipIsraeli
Alma materThe Hebrew University of Jerusalem
Known for
Scientific career
FieldsChemistry, Biochemistry
InstitutionsBar Ilan University
Saul Patai

Michael Albeck (Hebrew: מיכאל אלבק; born October 1934) is an Israeli organic and bioorganic chemist of tellurium compounds. He was President of Bar-Ilan University from 1986 to 1989.[1]

Early life and education

[edit]

Michael Albeck was born in Berlin, Germany to Hanoch and Henya Albeck in October 1934. His family immigrated to Mandatory Palestine in 1935 and settled in Jerusalem. He earned both MSc in Chemistry (1959) and PhD (1962) from The Hebrew University of Jerusalem.

Career

[edit]

He worked as Principal Investigator in the Institute for Fiber and Forest Products in Jerusalem in 1962-1964, as the head of the chemical laboratories of Mekorot Water Company in 1964-1965, and then he joined Bar Ilan University[2] as a faculty member at the Department of Chemistry, becoming a Full Professor in 1978. Albeck served as the Dean of The Faculty of Natural Sciences[3] of Bar Ilan University twice (1967-1969 and 1972-1975), as a member of the Board of Governors and the Board of Trustees of the university[4] (1982-1999) and as the university’s Rector (1982-1986) and President[5] (1986-1989; succeeding Emanuel Rackman, and succeeded by Ernest Krausz).[6] Since 2003, he is a Professor Emeritus at Bar Ilan.

Albeck assumed many scientific duties outside Bar Ilan University, including member of the boards of The Weizmann Scientific Press, Dead Sea Works, The German-Israel Binational Foundation (GIF),[7] Teva Pharmaceuticals, and as the President of The Israel Chemical Society.[8] Albeck is the son of the late Prof. Hanoch Albeck, who was a Professor of Talmud at the Hebrew University of Jerusalem and one of the foremost scholars of Judaic studies. Michael and his wife Shulamit, a retired Faculty member of the School of Social Work at Bar Ilan University, have four children, including chemistry professor Amnon Albeck, grandchildren and great grandchildren.

Scientific interests and publications

[edit]

Albeck’s main scientific interests are in the chemistry[9] and biological activity[10] of organic and inorganic tellurium compounds. Two of these compounds, AS101 and SAS, exhibit immuno-modulating, antiviral and anticancer activity. They are now in various clinical trials. He published over 120 scientific publications and patents.

References

[edit]
  1. "Bar-Ilan Presidents | Bar Ilan University". .biu.ac.il. Retrieved 2020-02-14.
  2. Department of Chemistry, Bar Ilan University
  3. Faculty of Exact Sciences, BIU
  4. Bar Ilan Board of Trustees
  5. "Bar-Ilan University - BIU | Israel". www.biu.ac.il. Retrieved 2025-05-21.
  6. "Bar-Ilan Presidents | Bar Ilan University". .biu.ac.il. Retrieved 2020-02-18.
  7. The German-Israeli Foundation for Scientific Research and Development (GIF)
  8. "ICSThe Israel Chemical Society". Retrieved 2025-05-21.
  9. Synthesis 1989, 8, 635, DOI:10.1055/s-1989-27344; Inorg. Chem. 1998, 37, 1704, DOI:10.1021/ic971456t; ChemMedChem 2007, 2, 1601, DOI:10.1002/cmdc.200700155.
  10. Nature 1987, 330, 173, DOI:10.1038/330173a0; Nat. Immun. Cell Growth Regul. 1990, 9, 182; Cancer Res. 1991, 51, 1499, available at http://cancerres.aacrjournals.org/content/51/5/1499.full.pdf+html; Nat. Immunol. 1993, 12, 50; J. Neurochem. 2003, 85, 90; Virus Res. 2012, 166, 68, DOI:10.1016/j.virusres.2012.03.004; Cancer Res. 2014, 74, 3092, DOI:10.1158/0008-5472.CAN-13-2159.